Flumazenil reverses the drowsiness and sedation that occurs when patients take a class of psychoactive drugs called benzodiazepines. The estimated U.S. market size for the drug is about $4 million.
Claris currently has 16 drug approvals, with 23 pending. The company expects more market approvals before the end of the year.
More articles on supply chain:
FDA fast tracks experimental drug to treat Parkinson’s
Roche’s Zika test earns FDA emergency use authorization
Mylan to introduce generic EpiPen at half the price
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
